Vaxart (STU:NB11) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


STU:NB11 Vaxart Inc STU:NB11
59 GF Score
Price €0.60
GF Value €9.39
! 3 Warning Signs
View Full Analysis

What is Vaxart Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vaxart's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:NB11 vs ANTX, CNTB, TTRX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vaxart's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vaxart's Margin of Safety % (DCF Earnings Based) falls into.


STU:NB11
59GF Score
Vaxart Inc STU:NB11
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 93.6% below its estimated GF Value™ of €9.39.

Key valuation signals for STU:NB11:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €9.39 vs. price of €0.60 (93.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
59GF Score

Get the complete analysis for STU:NB11

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€9.39
GF Value